Novel immunotherapeutic approaches to the treatment of diffuse large B-cell lymphoma (DLBCL), including recent approvals chimeric antigen receptor T-cell therapy, antibody-drug conjugates polatuzumab vedotin (PV) and loncastuximab tesirine-lpyl, anti-CD19 antibody tafasitamab, provide efficacious new options for patients with relapsed refractory disease. PV was first novel therapy approved in c...